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Abstract 
 
The Ras-association domain family (RASSF) has recently gained several new 
members and now contains ten proteins (RASSF1-10), several of which are 
potential tumour suppressors. The family can be split into two groups, the 
classical RASSF proteins (RASSF1-6) and the four recently added N-terminal 
RASSF proteins (RASSF7-10). The N-terminal RASSF proteins have a number 
of differences from the classical RASSF members and represent a newly defined 
set of potential Ras effectors. They have been linked to key biological processes, 
including cell death, proliferation, microtubule stability, promoter methylation, 
vesicle trafficking and response to hypoxia. Two members of the N-terminal 
RASSF family have also been highlighted as potential tumour suppressors. This 
review will summarise what is known about the N-terminal RASSF proteins, 
addressing their function and possible links to cancer formation. It will also 
compare the N-terminal RASSF proteins to the classical RASSF proteins and ask 
whether the N-terminal RASSF proteins should be considered as genuine 
members, or imposters in the RASSF family. 
 
 
Introduction 
Ras proto-oncogenes form part of a superfamily of small GTPases comprising of five 
families; Ras, Rho, Rab, Ran and Arf [1]. They play a pivotal role in a myriad of 
cellular processes, including cell growth, apoptosis, adhesion, migration and 
differentiation [2, 3]. Unsurprisingly then, defects in Ras signalling can result in 
disease progression, in particular oncogenesis. Indeed, Ras mutations resulting in 
signalling aberrations, frequently occur in human tumours, particularly in pancreatic 
and lung adenocarcinomas (Catalogue of Somatic Mutation in Cancer database 
(Cosmic) [http://www.sanger.ac.uk/genetics/CGP/cosmic/]). Ras proteins carry out 
their diverse functions by binding to a broad range of Ras effectors and blocking these 
interactions has been highlighted as an important therapeutic opportunity that could 
be exploited for cancer treatments [4]. However this requires a better understanding of 
the effector pathways utilised by Ras [4].  
 
Each Ras effector contains one of a number of Ras binding domains, as example is the 
RalGDS/AF6 Ras association (RA) domain. This conserved domain is the defining 
feature of members of the Ras association domain family (RASSF). The family now 
contains 10 members (RASSF1-10) which are split into two groups, the classical 
(RASSF1-6) and the amino terminal (N-terminal) RASSF proteins (RASSF7-10) [5]. 
Members of the classical RASSF proteins have been implicated in a range of 
biological processes, including the regulation of cell death, cell cycle control and 
microtubule stability, and are generally regarded as tumour suppressors. This has 
prompted great interest in these proteins and there are excellent reviews which mainly 
focus on the classical RASSF family [6-8] and in particular, RASSF1A [9-11]. 
Recently, four other proteins have been added to the family [5] and renamed 
RASSF7-10 (Table 1). These N-terminal RASSF proteins represent a new group of 
potential Ras effectors which may have important biological functions, some of which 
could well be distinct from previously studied Ras effectors. They may also have a 
role in cancer progression. In this review we will focus on the N-terminal RASSF 
proteins. We will summarise what is known about this newly described group of 
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proteins and ask is there any evidence to suggest a role for these proteins in cancer 
formation? We will also address the question of whether they should be considered as 
long lost members or imposters in the RASSF family.  
 
RASSF proteins are defined by the presence of a Ras association domain/ 
ubiquitin fold  
The defining feature of the RASSF proteins is the presence of a RA domain. This 
domain was identified by comparing sequences from different Ras binding proteins 
[12] and is present in over 50 human proteins (SMART database: http://smart.embl-
heidelberg.de/). However, the RA nomenclature is potentially misleading as it implies 
that a protein with this domain will bind Ras. In fact, the binding affinities of RA 
domains for members of the Ras family show a huge variation and not all will bind 
Ras [13, 14]. A good example of a RA domain which does not bind Ras is found in 
the class IX myosin protein, myr 5 [15]. All RA domains are believed to form a 
similar three dimensional structure called a ubiquitin fold [16], however the RA 
domain in myr 5 lacks positively charged amino acids which are required for Ras 
binding [15]. It is not surprising that only a subset of RA domains bind Ras, as the 
sequences of different RA domains are highly divergent [12]. There are also other 
ubiquitin fold containing proteins, such as FERM domain containing proteins and 
ubiquitin, which do not interact with Ras [16]. Another possible cause of confusion is 
the fact that other Ras effectors such as Raf and PI3K interact with Ras through a 
domain called a Ras binding (RB) domain. Despite the difference in nomenclature 
this domain also forms a ubiquitin fold [16]. Thus, Raf, PI3K, RASSF proteins, 
FERM domain proteins and ubiquitin all share a common structural domain and can 
be considered part of a ubiquitin fold family [13]. The variation in ability to bind Ras 
means that a key step in studying RA/ubiquitin fold proteins, such as the RASSF 
family members, is to establish if the proteins function as Ras effectors, something 
which will be discussed below.  
 
The classical and N-terminal RASSF proteins have different domain 
architectures 
The RA domain/ubiquitin fold of classical RASSF members is found near the carboxy 
(C)-terminal of the protein, adjacent to a protein-protein interaction domain called the 
SARAH domain (Fig. 1). This domain is named after the 3 types of proteins that 
contain it; Salvador (WW45 in vertebrates), RASSF and Hippo (MST1/2 in 
vertebrates) [17]. SARAH domains have two α-helices which form a novel dimeric 
anti-parallel helix [18]. Dimerisation between SARAH domains allows Salvador, 
RASSF and Hippo to form homo and heterodimers. RASSF1 and 5 also contain a 
diacylglycerol/phorbol ester binding (DAG) domain (Fig. 1), known as protein kinase 
C conserved region (C1). In RASSF5/Nore1 the C1 domain can form an 
intramolecular complex with the RA domain/ubiquitin fold and when free bind the 
lipid phosphatidylinositol 3-phosphate[19]. 
 
The N-terminal RASSF proteins have a different domain architecture to the classical 
RASSFs (Fig. 1A). The RA domain/ubiquitin fold of the N-terminal members is 
located at the opposite end to the C-terminal location found in the classical RASSF 
proteins. The RA domains/ubiquitin folds of the two groups also have quite different 
sequences which form phylogenetically distinct groups (Fig. 2). In addition to the 
differences in RA domains/ubiquitin folds the N-terminal RASSF members lack an 
identifiable SARAH motif [5, 17]. However, some caution may be required on this 
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point. The SMART database predicts that RASSF7, 8 and 10 have extensive regions 
of coiled coil and like SARAH domains, coiled coils can form dimers mediated by 
hydrophobic residues [20]. Structural studies are required to confirm there is no 
similarity between the coiled coils of the N-terminal RASSF proteins and SARAH 
domains of the classical proteins.  
 
RASSF7, 8 and 10 are all located close to members of the Ras family in the genome 
[5, 21, 22]. This suggests that the N-terminal RASSF proteins may have co-evolved 
with members of the Ras family. We have not found a similar association between the 
classical RASSFs and members of the Ras family, so this unusual juxtaposition of a 
Ras gene and a potential Ras effector represents another distinction between the two 
groups. The separation between N-terminal and C-terminal RASSF genes is not a 
recent event, Drosophila and C elegans have both classical (dmRASSF [23] and 
T24F1.3 [24]) and N-terminal RASSF (Table 1 and [5]) homologues. The differences 
between classical and N-terminal RASSF proteins prompted us to suggest they are 
distinct families, with the N-terminal RASSF proteins representing a new group of 
RA domain/ubiquitin fold containing proteins [5].  
 
Classical RASSF proteins act as tumour suppressors 
The focus of this review is the N-terminal RASSF proteins, however, before covering 
these proteins in detail we will summarise what is known about the six classical 
RASSF (RASSF1-6) proteins. This is not intended to replace comprehensive reviews 
of the family [6-8], but to allow a comparison with the N-terminal RASSF members. 
 
RASSF1 was originally identified in a yeast-2-hybrid screen and the gene was found 
to reside at chromosome 3P21.3 [25], a region long suspected to contain at least one 
tumour suppressor [26]. The expression of one of the RASSF1 transcripts, RASSF1A, 
was found to be repressed by promoter hypermethylation in lung tumours [25]. 
Subsequent studies found that RASSF1A was inactivated by methylation in a wide 
range of tumours (e.g. [27]) and it quickly emerged that RASSF1A is one of the most 
frequently methylated genes in cancer [9-11]. Restoring expression of RASSF1A 
reduces tumour growth and knocking out RASSF1A in mice causes an increased 
frequency of tumour formation [28, 29]. These studies provide convincing evidence 
that RASSF1A is a tumour suppressor, which is inactivated in a wide range of cancers. 
Inactivation by promoter methylation occurs with several other members of the 
classical RASSF family in human tumour cells, including RASSF2, 4 and 5 [6-8], 
suggesting that they may also be tumour suppressors. Understanding why RASSF1A 
and other members of the classical RASSF family act as tumour suppressors has been 
far from straight forward, due to the variety of biological roles they possess. Classical 
RASSF proteins have been linked to a range of processes, particularly the regulation 
of apoptosis, cell cycle progression and microtubule stability. 
 
Classical RASSF proteins are key regulators of apoptosis  
RASSF family members have been linked to promoting apoptosis through a number 
of effectors [6-8]. One group of effectors are the proapoptotic kinases MST1 and 
MST2, which bind members of the classical RASSF family [24, 30, 31]. Hippo, the 
Drosophila homologue of MST1, forms part of an important tumour suppressor 
network which is crucial for growth control [32, 33]. Hippo functions by regulating 
the kinase Warts which in turn regulates the transcriptional activator Yorkie, which 
controls apoptosis-associated genes. Recent work shows that RASSF1A induced 
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apoptosis acts via a similar pathway, which involves MST2 activating LATS, causing 
the release of YAP which promotes transcription of p73 [34]. NDR (Nuclear Dbf2-
related) kinases, which are related to LATS kinases, can also function down stream of 
MST1 to promote apoptosis [35]. In addition to MST1/2, classical RASSF proteins 
bind another positive regulator of apoptosis, MOAP1 [36-38]. After death receptor 
signalling, MOAP-1 and RASSF1A are recruited to the death receptor where the 
interaction of RASSF1A with MOAP-1 allows MOAP-1 to activate Bax and promote 
apoptosis [36, 39].  
 
Classical RASSF proteins are important for microtubule stability and cell cycle 
progression 
A second function of the classical RASSF proteins is to regulate the cell cycle. 
Expression of RASSF1A blocks cell cycle progression at a number of stages, 
including G1, G2-M and in prometaphase [40-43]. The RASSF1A induced arrest in G1 
is associated with reduced activity of c-Jun-NH2-kinase (JNK) [44] and activator 
protein -1 (AP1) [45], which both promote cell cycle progression. RASSF1A also up 
regulates expression of the cyclin dependant kinase inhibitor p21Cip1/Waf1[46]. These 
effects are likely to be mediated by a number of effectors. RASSF1A can bind MDM2 
and death-domain-associated protein (DAAX). This prevents degradation of the 
tumour suppressor p53, which would allow p53 to promote cell cycle arrest [47]. 
RASSF1A can also bind and increase the activity of p120 E4F, a transcriptional 
repressor of Cyclin A2 [48, 49].  
 
The RASSF1A induced arrest in mitosis is tightly associated with the ability of 
RASSF1A to associate with microtubules. RASSF1A can bind and stabilise 
microtubules [41, 43, 50, 51], probably via interacting with a number of microtubule 
associated proteins [50, 52].  Once bound to microtubule associated proteins 
RASSF1A appears to function as a scaffold, recruiting multiple regulators of mitosis. 
Current data suggests these may include Mst1/2, Cdc20, Aurora-A and Ran.  Mst1 
could signal through the Hippo pathway (see above) to regulate mitotic progression 
[53]. RASSF1A can also bind and inhibit Cdc20, which activates the anaphase 
promoting complex [54], although it should be noted that this interaction is 
controversial [55]. RASSF1A is phosphorylated by the mitotic kinase, Aurora-A [56], 
and can regulate the activity of Aurora-A [57]. Finally it has recently been shown that 
Ran can act as a RASSF1A effector to regulate microtubule stability [58]. In addition 
to mitosis RASSF1A has been linked to cell migration, which is consistent with a role 
in regulating microtubules [59].  
 
Other members of the classical RASSF family have been linked to cell cycle 
progression. An example is RASSF5/Nore1, which shows striking similarities to 
RASSF1A. RASSF5/Nore1 can associate with microtubules [60] and suppress growth 
by a mechanism which involves p53 activating the expression of p21Cip1 [61]. In 
summary, classical RASSF proteins have been linked to apoptosis, cell cycle control 
and the regulation of microtubule stability, all of which may contribute to the tumour 
suppressor function of these proteins.  
 
Classical RASSF proteins and Ras 
The presence of a RA domain/ubiquitin fold suggests the classical RASSF proteins 
will act as Ras effectors. However, as discussed above, not all RA domains bind Ras, 
and for many of the classical RASSF proteins it is not clear if they function as Ras 
 6
effectors to mediate the processes described above. RASSF5/Nore1 is perhaps the 
best documented Ras effector of the RASSF family. The splice variant 
RASSF5A/Nore1A was identified as a Ras interacting protein by yeast-two-hybrid 
and the endogenous protein interacts with Ras following addition of EGF [62]. 
RASSF5A/Nore1A is also the first member of the RASSF family to have the crystal 
structure of its RA domain/ubiquitin fold determined [63]. This was carried out in 
complex with Ras and demonstrated that the region which interacts with Ras is 
extended compared with other Ras effectors. This lengthened interface provides the 
RASSF5A/Nore1A – Ras complex with a prolonged lifetime compared to other Ras 
effectors. However, a physiological role for a RASSF5A/Nore1A-Ras complex is yet 
to be identified. The splice variant RASSF5B/Nore1B (also known as RAPL) is a Ras 
effector with a well documented physiological role in T cell signalling, where it 
associates with the Ras protein Rap1 [64].   
 
RASSF1A can bind Ras in a GTP dependant manner [65], but it binds with a much 
lower affinity than RASSF5/Nore1 [63, 66]. This raises the question, is RASSF1A a 
genuine Ras effector? An endogenous RASSF1A-Ras complex has been described 
[67], but similar to the RASSF5A/Nore1A-Ras complex, the physiological role of this 
complex is not known. A recent twist to this story is that RASSF1A can bind to the 
small GTPase Ran [58] and regulate microtubule organisation (discussed above). The 
binding appears direct and can be seen with endogenous protein. Ran is not a member 
of the Ras family but is part of the large superfamily of related small GTPases [1]. 
This suggests that RASSF1A functions by binding Ran in addition to, or instead of, 
binding Ras. It also raises the possibility that RASSF1A and other RASSF proteins 
might bind other small GTPases in addition to Ras and Ran. Future work is required 
to untangle the biology of the classical RASSF proteins and the role that Ras and 
other small GTPases play in their function.  
 
The N-terminal RASSF family 
The difference in domain architecture and sequence of the RA domains prompted us 
to propose that the N-terminal RASSF proteins are a distinct family from the classical 
RASSF proteins [5]. This makes the decision to add them to the RASSF family look 
questionable. However, one crucial benefit of the renaming is to group the N-terminal 
RASSF proteins together for the first time. This makes it possible to compare what is 
known about each member. To achieve this we have searched the literature for work 
relating to each N-terminal RASSF protein. We used the 11 different names which 
have been given to the vertebrate members (Table 1) and it is important to point out 
that many of the references cited here use the older nomenclature. Given the 
importance of the work on the Drosophila classical RASSF protein [23], we have also 
looked at the three potential N-terminal Drosophila members. In the following 
sections we will summarise what is known about each of the N-terminal RASSF 
proteins and where appropriate relate it back to what is known about the classical 
RASSF proteins. 
 
RASSF7: The first RASSF protein to be described? 
RASSF7 was originally identified by a study which set out to sequence genes which 
are located close to HRas in the genome [21]. The authors found an unstudied gene 
and called it Hras1 cluster 1, HRC-1. HRC-1 was recently renamed RASSF7, 
presumably because the protein it encodes contains an RA domain/ubiquitin fold and 
was not part of a recognised family. The hypothesis of the authors who identified 
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RASSF7/HRC-1 was that it might be a growth regulator because it was close to HRas 
in the genome [21]. They also suggested, based on Southern blotting, that 
RASSF7/HRC-1 might be part of a large family of related proteins. This was six years 
before RASSF5/Nore1 was identified as a potential Ras effector [62] and it is only 
recently that the authors predictions about RASSF7 have begun to be confirmed.  
 
The genomic position of RASSF7 places it in close proximity to the HRAS1 
minisatellite which is immediately down stream of HRas. Rare alleles of this 
minisatellite were shown to be associated with cancer risk [68, 69] and it was 
proposed that altered expression of RASSF7 might contribute to the increased risk 
[70]. This generated a great deal of interest in the region, however subsequent studies 
using improved technology failed to find a link [71, 72] and the idea that rare alleles 
of the minisatellite are associated with cancer risk has fallen from favour.   
 
RASSF7: a hypoxic response gene which is up regulated in certain cancers. 
The advent of genomic screening technology has made it possible to interrogate the 
entire genome for genes which are misregulated in cancer. Several microarray studies 
have shown that RASSF7 is up regulated in cancer (Table 2). One example is in 
pancreatic cancer. Two independent studies have found that RASSF7 expression is 
increased in pancreatic ductal adenocarcinoma relative to normal tissue [73-75]. In 
addition to ductal adenocarcinoma, RASSF7 has increased expression in a second type 
of pancreatic cancer, islet cell tumours [76]. This study selected RASSF7 as a key 
gene whose expression can be used to identify islet cell tumours. RASSF7 expression 
is also increased in endometrial cancer [77]. Similar to the situation in islet cell 
tumours, RASSF7 showed a large increase in expression and was selected as one of 
the top 50 genes which distinguish malignant from normal endometrium. Finally 
RASSF7 lies in a genomic region which is amplified in ovarian clear cell carcinoma 
and its expression is increased in these cancers, correlating with the genomic 
amplification [78].   
 
Interestingly, recent work offers plausible explanations as to why RASSF7 may be up 
regulated in cancer samples. Hypoxia, which occurs in solid tumours, is known to 
cause a large number of gene expression changes [79] and RASSF7 expression was 
found to be up regulated by hypoxia in MCF7 breast cancer cells [80] and in human 
umbilical vein endothelial cells [81]. This predicts that the hypoxic environment 
found in solid tumours would cause an increase in RASSF7 expression. Furthermore, 
RASSF7 is also down-regulated by the tumour suppressor, BRCA1, suggesting its 
expression would be increased in cancer cells which have lost BRCA1 function [82].  
 
RASSF7 is required for cell death and proliferation 
An important question is what role RASSF7 plays in these cancerous cells? There is 
currently no evidence to suggest that increased expression of RASSF7 promotes 
cancer formation. However, RASSF7 function has been linked to some key biological 
processes including the regulation of cell death and proliferation. RASSF7 has been 
shown to be required for necroptosis [83], a regulated form of necrosis which is 
distinct from apoptosis. A large scale siRNA screen was carried out to find proteins 
required for necroptosis and this identified RASSF7 and RASSF8.  
 
We identified Xenopus RASSF7 in a microarray screen [84] and subsequently found 
that in Xenopus, RASSF7 is essential for cell cycle progression and cell survival [5]. 
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In cells where RASSF7 is knocked-down, mitotic spindles fail to form and cells arrest 
in mitosis. This causes nuclear fragmentation and apoptosis. Consistent with a role in 
mitotic progression, Xenopus RASSF7 is localised at the centrosome. However, 
Xenopus RASSF7 is not a core component of the centrosome, rather it appears to be 
enriched at the centrosome because it interacts with the minus ends of microtubules. 
Preliminary data from a large scale screen suggests that the Drosophila homologue 
may also be required for cell proliferation. Knockdown by RNA interference caused a 
reduction in the mitotic index and weak spindle defects [85].  
 
RASSF7, like other RASSF proteins, contains no catalytic domain so to understand 
its function it is crucial to identify the proteins it interacts with. Yeast-2-hybrid studies 
have identified potential binding partners for human RASSF7. These include 
CHMP1B, which is associated with endosomal membrane trafficking, and DISC1 
which interestingly interacts with microtubules [86, 87].  
 
RASSF8 is located in a genomic region associated with lung cancer risk 
The sequence for RASSF8 was first deposited into the NCBI data base by Hoon and 
Yuzuki in 1996 (accession number Q8NHQ8) and called ‘human carcinoma 
associated HoJ-1’. However, there appears to have been no publication associated 
with this submission. Subsequently, RASSF8 was characterised as a gene involved in 
a chromosomal translocation associated with a complex type of synpolydactyly [88, 
89]. RASSF8 was found to be located on chromosome 12 and referred to as C12orf2. 
The chromosomal translocation fused RASSF8 with the fibulin-1 gene (22q13.3). It is 
believed that this disrupts a fibulin-1 splice variant, causing the synpolydactyly. 
C12orf2 was then renamed RASSF8, presumably because it contains a RA 
domain/ubiquitin fold and was not part of a recognised family. This occurred at the 
same time as HRC-1 was renamed RASSF7 and both proteins were added to the 
RASSF family. 
 
RASSF8 is located about 700 Kb from the KRas2 gene [22] and both genes lie in a 
region called Pals1. This region has been identified as a major susceptibility locus in a 
mouse model for lung carcinogenesis [90]. There are a number of genes in this region 
but it is mutations in the KRas2 gene that are believed to be responsible for the 
increased risk [91]. The homologous region in humans has also been associated with 
increased lung adenocarcinoma risk [92]. However, in humans it is not clear if it is 
KRas2 that is responsible. Analysis of the region in a Japanese population, identified 
the D12S1034 microsatellite as being most tightly associated with lung cancer risk 
[93]. The D12S1034 locus showed a bigger difference between cases and controls 
than the microsatellite adjacent to KRas2. This argues that in some human cancers, 
susceptibility may be due to a mutation in a gene adjacent to D12S1034 rather than in 
KRas2 itself. RASSF8 lies within 20 Kb of D12S1034 making it a good candidate 
gene, particularly as RASSF8 has also been described as a potential tumour 
suppressor in lung cancer (see below). However, common polymorphisms in RASSF8 
are not associated with cancer risk in an Italian population [94]. Thus, currently it is 
not clear if there is the link between RASSF8 and the increased lung cancer risk 
associated with the Pals1 region. 
 
RASSF8 is a potential tumour suppressor 
There are several lines of evidence to suggest that RASSF8 may be a tumour 
suppressor (altered expression levels are summarised in Table 2). The best 
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characterised example is in lung cancer [22]. In lung adenocarcinoma RASSF8 
transcript levels were reduced compared with normal tissue. Over-expression of 
RASSF8 protein in lung cancer cell lines also inhibited anchorage-independent 
growth, which has been correlated with tumour progression and metastasis. In 
addition to lung adenocarcinoma, RASSF8 expression is also down-regulated in male 
germ cell tumours [95], despite the fact that the gene lies in a genomic region which 
shows gain in almost 100% of these cancers. Finally, RASSF8 was identified as a 
candidate gene involved in leukaemia and lymphoma formation in a study on 
retroviral-induced blood cancers in mice [96]. This model assumes that oncogenes 
and tumour suppressors often lie near common retroviral insertion sites. A genomic 
region next to RASSF8 was targeted seven times, making it one of the most frequently 
hit sites in the study. This suggests that mis-regulation of RASSF8 may contribute to 
leukaemia and lymphoma formation, so it is interesting that RASSF8 has higher 
expression in human hematopoietic stem cells and is required for blood cell 
development in Zebrafish [97]. It is not known why RASSF8 might be a tumour 
suppressor but it is interesting that, similar to RASSF7, it is required for cell death by 
necroptosis [83]. This form of cell death may be particularly important in cells with 
deficiencies in their apoptotic machinery, such as tumour cells, so a role in 
necroptosis would be consistent with a tumour suppressor function. 
 
Mass spectrometry and yeast-2-hybrid screens have identified a number of potential 
binding partners for RASSF8; including the scaffolding protein, 14-3-3γ which binds 
phosphoproteins to modulate their function [98]; and FRMD4, an ERM (Ezrin, 
Radixin, Moesin) protein that links membrane domains to actin and PSMD4, a 
component of the proteosome [99]. These potential binding partners offer interesting 
leads for future work aimed at understanding why RASSF8 may function as a tumour 
suppressor. 
 
RASSF9 is a Ras binding protein that has been linked to vesicle trafficking 
RASSF9 was first identified by a yeast-2-hybrid screen as a protein that interacted 
with the cytoplasmic domain of peptidylglycine alpha-amidating monooxygenase 
(PAM) [100]. Based on this interaction it was named PAM C-terminal interactor 1 (P-
CIP1). PAM is a transmembrane protein found in secretory vesicles of neurons and 
endocrine cells, where it catalyses the α-amidation of bioactive peptides such as 
oxytocin and vasopressin. This modification is essential for the activity of these 
peptides [101]. We realised that PCIP-1 contains an RA domain/ubiquitin fold and is 
closely related to RASSF7+8 and suggested it should be renamed RASSF9 [5]. The 
binding of RASSF9/P-CIP1 to PAM was confirmed and RASSF9/P-CIP1 was found 
to associate with recycling endosomes [102]. This led to the model that it might bind 
the cytoplasmic domain of PAM during recycling of the enzyme [102], an interaction 
that may be regulated by phosphorylation as the cytoplasmic domain of PAM is 
known to be multiply phosphorylated [103]. However, RASSF9 mRNA is expressed 
much more widely than PAM, so RASSF9 might have additional roles, perhaps 
binding other transmembrane proteins.  
 
Interestingly RASSF9 is the one member of the N-terminal RASSF proteins which 
has been shown to bind RAS proteins. Pull down experiments with RASSF9 and Ras 
family GTPases showed that RASSF9 binds N-Ras, K-Ras and R-Ras [14]. An issue 
that remains to be addressed is whether RASSF9 binds endogenous Ras, or other 
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small GTPases, something which has not been straightforward to answer for the 
classical RASSF proteins (see above).  
 
RASSF10 is a candidate tumour suppressor in childhood leukaemia 
We discovered that a predicted protein was similar in sequence to RASSF9 and 
named this protein RASSF10 [5]. This gene was completely unstudied, until recent 
work showing that it is a candidate tumour suppressor in childhood leukaemias [104]. 
The transcript of RASSF10 was characterised and found to be shorter than the 
predicted version. The protein encoded by the shorter version is more similar to 
RASSF7-9 and is used in Figure 1. RASSF10 contains a large CpG island and given 
the frequent inactivation of classical RASSFs by promoter hyper methylation (see 
above) the authors examined the methylation status of this gene in childhood 
leukaemia. They found that RASSF10 was frequently methylated in leukaemia cell 
lines (100%) and T cell acute lymphocytic leukaemias (T-All) (88%), but not in 
normal bone marrow and blood samples. RASSF10 was also rarely methylated in B-
ALL (16%). Inhibiting this methylation caused an upregulation of expression in the 
leukaemia cell lines. This data strongly suggests that RASSF10 expression is inhibited 
by promoter methylation in a high percentage of T-All, raising the possibility that 
RASSF10 might function as a tumour suppressor in these cancers. ESTs for RASSF10 
are present in a number of tissues [104] and it will be interesting to see if RASSF10 is 
methylated in tumours derived from these tissues.  
 
The function of RASSF10 remains unstudied in vertebrates. There is a potential 
Drosophila homologue (Table 1). However little is known about this gene except that 
it is expressed in precursors of the peripheral nervous system [105], and knocking 
down its function impairs Hedgehog signalling [106]. RASSF10 offers exciting 
opportunities for future study. 
 
Concluding remarks 
The N-terminal RASSF proteins have a different domain architecture from the 
classical RASSF proteins and so we proposed that they should be considered as a 
separate family [5]. Donninger and colleagues came to a similar conclusion for 
RASSF7 and 8, suggesting that they are a separate sub-family distinct from the ‘true’ 
RASSF proteins [10]. If the N-terminal and classical RASSF proteins are members of 
different families then one might expect that there will be little overlap between their 
biology. However, RASSF7 and RASSF1A show similar centrosomal localisation and 
mitotic defects when knocked down and RASSF10 and members of the classical 
RASSF family both show promoter hypermethylation. These similarities might 
suggest that the N-terminal RASSF proteins are genuine RASSF proteins. However, 
we feel the differences between them still outweigh the similarities and that the N-
terminal RASSF proteins are not ‘true’ RASSF proteins, but a separate family. 
Emerging evidence presented in this review suggests that the N-terminal RASSF 
proteins might play a role in tumour formation (summarised in Fig. 3). There is now 
an exciting opportunity to study this new group of proteins in more detail and confirm 
whether they are important in oncogenic progression.  
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Figure Legends 
 
Figure 1. N-terminal RASSF proteins are structurally distinct from the classical 
RASSF proteins.  
The N-terminal RASSF proteins comprise a recently identified set of RA 
domain/ubiquitin fold containing proteins. Their domain architecture is distinct from 
the classical RASSF proteins suggesting they should be considered as a separate 
group. Sequences used for the domain analysis were; hsRASSF1A (NP_009113), 
hsRASSF2 (NP_055552), hsRASSF3 (NP_835463), hsRASSF4 (NP_114412), 
hsRASSF5/splice variant NORE1A (NP_872604), hsRASSF6B (NP_958834), 
hsRASSF7 (NP_003466), hsRASSF8 (NP_009142), P-CIP1/RASSF9 (AAD03250) 
and RASSF10 (NP_001073990, the short version described in [104]). Adapted from 
Figure 1 in [5]. 
 
Figure 2. The RA domains of the classical and N-terminal RASSF proteins are 
phylogenetically distinct.  
The phylogeny of the RA domains from RASSF1-10, ten other RA domains from 
nine other proteins (AF6 has two RA domains), and a yeast outlier was inferred. The 
analysis was carried out by profile aligning the RA domains to the alignment of RA 
domains from the SMART database, using ClustalW. Phylogenetic inference was then 
carried out using neighbor-joining, parsimony and maximum likelihood methods from 
PHYLIP3.67. There was some variation in the tree topologies, but with each method 
the RA domains from the classical and N-terminal proteins clustered in two well 
separated monophyletic  groups. The tree here shows the maximum likelihood 
inference using the Jones-Taylor-Thornton model. RA domains from the following 
sequences were used; RASSF1A (NP_009113.3), RASSF2 (NP_055552.1), RASSF3 
(NP_835463.1), RASSF4 (NP_114412.2), RASSF5 (NP_872604.1), RASSF6 
(NP_803876.1), RASSF7  (NP_003466.1), RASSF8 (NP_009142.2), RASSF9 
(AAD03250.1), RASSF10 (NP_001073990.1), STE50 (P25344), Rap1 
(AF478469_1), A4beta (EAW86096.1), GRB10 (Q13322), MYOIXb (Q13459), 
GRB7 (NP_005301.2), DGKtheta (P52824), PhosC (Q5VWL4), AF-6 
(BAA32485.1).  
 
 
Figure 3. Emerging evidence suggests a possible link between the N-Terminal 
RASSF proteins and cancer progression.  
A summary of the evidence suggesting that the N-terminal RASSFs may play a role in 
tumourigenesis. Data consistent with potential anti-tumourigenic roles are indicated 
by red arrows, whilst evidence suggesting pro-tumourigenic roles are indicated by 
green arrows. Broken arrows highlight links which may be anti- or pro-tumourigenic. 
The cellular localisation is given where it is known. Full details and references are 
provided in the review text. 
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Tables 
 
 
N-terminal 
RASSF 
member 
Chromosome   Alternative names Potential 
Drosophila 
homologue 
Potential  
C. elegans 
homologue 
RASSF7 11p15.5 HRAS1 cluster1 (HRC1),  
C11orf13 
RASSF8 12p12.3 Human carcinoma associated HoJ-
1(HoJ-1), 
C12orf2 
 
CG5053 
RASSF9 12q21.31 peptidylglycine alpha-amidating 
monooxygenase (PAM) C-terminal 
interactor 1 (P-CIP1), 
PAMC1 
CG13875* 
RASSF10 11p15.2 similar to peptidylglycine alpha-
amidating monooxygenase C-
terminal interactor 1 
CG32150* 
 
 
 
 
K05B2.2* 
Table 1. N-terminal RASSF family.  
The table summarises the nomenclature used for the N-terminal RASSF proteins. The 
genes marked with a * are not predicted to have an RA domain by the SMART 
database, however they do have sequence similarity over the RA domain region of the 
vertebrate N-terminal RASSF protein, thus can be considered as potential 
homologues. 
 
 
 
Gene Tumour type Change Reference 
Pancreatic 
adenocarcinoma 
Up-regulated 
 
[74] + [75] 
Islet cell tumour Up-regulated [76] 
Endometrial carcinoma Up-regulated [77] 
 
 
RASSF7 
Ovarian clear cell 
carcinoma 
Amplified and 
up-regulated 
[78] 
Lung adenocarcinoma Down-regulated [22] RASSF8 
Male germ cell tumours Down-regulated [95] 
RASSF10 T cell acute lymphocytic 
leukaemia 
Down-regulated by 
promoter methylation 
[104] 
Table 2. Aberrant expression of the N-terminal RASSFs in cancer cells. 
The table presents a summary of manuscripts reporting aberrant expression of N-
terminal RASSF members in cancer. There are other examples in the Oncomine data 
base (http://www.oncomine.org/), but we have only included those where we can find 
reference to the N-terminal member in the primary paper or supplementary material. 
It is important to note that these papers often use the alternative gene names described 
in Table 1. 
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Figure 3 Sherwood et al. 
